期刊文献+

EGFR与PI3K/AKT信号通路相关蛋白在非小细胞肺癌组织中的表达及其意义 被引量:17

The role of EGFR and PI3K/AKT signal pathway in non-small cell lung cancer
暂未订购
导出
摘要 目的研究表皮生长因子受体(EGFR)和磷酸肌醇3激酶、丝氨酸/苏氨酸蛋白激酶信号通路相关蛋白在非小细胞肺癌(NSCLC)组织中的表达以及其临床意义。方法应用免疫组化学SP法检测100例NSCLC组织及其相应正常癌旁组织中的EGFR、PI3K、AKT蛋白表达水平。结果 100例正常的癌旁组织中EGFR、PI3K及AKT蛋白的阳性表达率分别为13%、11%、7%,100例NSCLC组织中EGFR、PI3K及AKT蛋白的阳性表达率分别为63%、51%、23%,两种组织的3种阳性表达率差异均有统计学意义(P<0.05)。结论 EGFR可能通过激活其下游的PI3K/AKT通路发挥致癌作用。 Objective To explore the role of epidermal growth factor (EGFR) and phosphotylinosital 3 kinase/serine threonine protein kinase (PI3K/AKT) signal pathway in non-small cell lung cancer(NSCLC). Methods The immunohistochemical SP method was used to measure the protein expression of EGFR, PI3K and AKT in the 100 cases of NSCLC and normal paracancerous tissues. Results The positive expression rate of EGFR,PI3K and AKT was 13%, 11% and 7% respectively in the normal paracancerous tissues, while the positive expression rate of EG- FR,PI3K and AKT in the NSCLC was 63% ,51% and 23% , which showed significant statistical difference (P 〈 0.05 ). Conclusion The expression of the EGFR, PI3 K and AKT in NSCLC is higher than those in the normal paracancerous tissues, so EGFR may play a key role in its cancerogenesis by activating the down stream pathway of PI3K/AKT in NSCLC.
出处 《安徽医科大学学报》 CAS 北大核心 2011年第12期1264-1266,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽医科大学中青年学术骨干基金[编号:校人字(2009)38]
关键词 表皮生长因子受体 磷酸肌醇3激酶 丝氨酸∕苏氨酸蛋白激酶 非小细胞肺癌 免疫组化 EGFR PI3K/AKT non-small cell lung cancer immunohistochemical
  • 相关文献

参考文献8

  • 1Lopez-Chavez A, Carter C A, Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer [J]. Curr Opin Investig Drugs, 2009,10 (12): 1305 - 14.
  • 2Jean Y K, S W, Chung J H, et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non - small cell lung cancer [J]. Lung Cancer, 2006, 54 (3) : 387 -92.
  • 3于敏,倪琛琛,刘善青,许晓兰,张志红.EGFR、pEGFR蛋白在非小细胞肺癌中的表达及临床意义[J].安徽医科大学学报,2011,46(1):57-60. 被引量:8
  • 4Silvestris N, Tommosi S, Petriella D, et al. The dark side of the moon: the PI3K/PTEN/AKT pathway in eoloreetal carcinoma[J]. Oneology,2009,77(Suppl) 1 : 69 -74.
  • 5Chen C H, Lai J M, Chou T Y, et al. VEGFA upregulates FLJ 10540 and modulates migration and invasion of lung cancer via PI3 K/AKT pathway [J]. PLoS One, 2009,4 (4) :50 - 2.
  • 6岳文涛,王小敏,王玥.PI3K/Akt/mTOR信号转导途径与非小细胞肺癌的关系[J].中国肺癌杂志,2009,12(4):312-315. 被引量:29
  • 7Shaw R J, Cantley L C. Ras, PI3K and mTOR signaling controls tumour cell growth [ J ]. Nature, 2006,441 (7092) :424 - 30.
  • 8王芳,符立梧.多靶点抗肿瘤新药索拉非尼的研究进展[J].中国药理学通报,2008,24(8):1117-1120. 被引量:24

二级参考文献42

  • 1郑杰.mTOR信号途径与肿瘤[J].生命科学,2006,18(3):261-265. 被引量:20
  • 2Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J, 2004, 6(4): 589-604.
  • 3Shaw R J, Cantley LC. Ras, PI(3)K and mTOR signalling controls lumour cell growth. Nature, 2006, 441(7092): 424-430.
  • 4Massion PP, Taflan PM, Shvr Y et al. Early involvement of the phosphalidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med, 2004, 170(10): 1088-1094.
  • 5Dudek H, Datta SR, Franke TF, et al. Regulation of nenronal survival by the serine-threonine protein kinase Akt. Science, 1997, 275(5300): 661-665.
  • 6Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activalion of mTOR/S6K signaling. Clin Cancer Res, 2006, 12(3): 710-717.
  • 7Hanaban D. Signaling vascular morphogenesis and maintenance. Science, 1997, 277(5322): 27748-27750.
  • 8Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995, 1(1): 27-31.
  • 9Li CY, Shan S, Huang Q, et al. Initial stage of tumor cell-induced angiogenesis: Evalution via skin window chambers in rodent models. J Natl Cancer Inst, 2000, 92(2): 143-147.
  • 10Wilhelm S M,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[ J]. Cancer Res,2004,64(19) :7099 - 109.

共引文献58

同被引文献231

引证文献17

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部